An observational study in Growth Hormone Deficiency, Idiopathic Short Stature and Turner Syndrome, sponsored by Dong-A ST Co., Ltd.. Recruiting at 1 site in South Korea. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Dong-A ST Co., Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.
252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.
This study's planned enrollment of 5,000 is above the median of 70 across 73 observational studies indexed under Dwarfism, Pituitary.
Browse Dwarfism, Pituitary studies →Dong-A ST Co., Ltd. is the lead sponsor of 122 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Short stature by GHD or ISS or TS or SGA
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Growtropin®-II
Long term safety assessed through the adverse events
Number of occurrence of treatment-related adverse events
Time frame: Up to 2 years after epiphyseal closure
Change of annualized height velocity
To assess the difference in change of annualized height velocity between baseline and every 6 months
Time frame: Up to 2 years after epiphyseal closure
The difference between target height and final height
To assess the difference in target height and final height
Time frame: Up to 2 years after epiphyseal closure
Changes in Height SDS
To assess the changes in Height SDS between baseline and every 6 months
Time frame: Up to 2 years after epiphyseal closure
Changes in skeletal maturity
To assess the changes in skeletal maturity between baseline and every 6 months
Time frame: Up to 2 years after epiphyseal closure
Changes in IGF-1
To assess the changes in IGF-1 between baseline and every 6 months
Time frame: Up to 2 years after epiphyseal closure
Changes in IGFBP-3
To assess the changes in IGFBP-3 between baseline and every 6 months
Time frame: Up to 2 years after epiphyseal closure
Changes in BMI SDS
To assess the changes in BMI SDS between baseline and every 6 months
Time frame: Up to 2 years after epiphyseal closure
Started Feb 2021 (actual). Primary completion is estimated for Feb 2035, 168 months after the start.
Of 30 observational studies under Dwarfism, Pituitary, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 102. This study's planned 168 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.